CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

10 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10

03 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

19 Jul 2022 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study

27 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference

17 Jun 2022 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

25 May 2022 09:00:02 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

18 May 2022 09:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

10 May 2022 16:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

03 May 2022 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit

29 Mar 2022 09:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

28 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy

11 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

10 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10

03 Mar 2022 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development

02 Mar 2022 09:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.

25 Jan 2022 05:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19

13 Dec 2021 09:15:00 By Nasdaq GlobeNewswire

Capricor’s CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day

12 Nov 2021 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

09 Nov 2021 16:05:02 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9

02 Nov 2021 16:05:01 By Nasdaq GlobeNewswire